2024-12-01 2025-11-30 2025-11-30 false 02575564 Selective Antibodies Limited 72110Research and experimental development on biotechnology iso4217:GBP xbrli:pure 025755642024-12-01 025755642025-11-30 025755642024-12-01 2025-11-30 02575564bus:Micro-entities2024-12-01 2025-11-30 02575564bus:AuditExempt-NoAccountantsReport2024-12-01 2025-11-30 02575564bus:FullAccounts2024-12-01 2025-11-30 02575564core:WithinOneYear2025-11-30 02575564core:AfterOneYear2025-11-30 02575564core:WithinOneYear2024-12-01 2025-11-30 02575564core:AfterOneYear2024-12-01 2025-11-30 02575564core:CurrentFinancialInstruments2025-11-30 02575564core:Non-currentFinancialInstruments2025-11-30 02575564core:CurrentFinancialInstruments2024-12-01 2025-11-30 02575564core:Non-currentFinancialInstruments2024-12-01 2025-11-30 02575564core:LandBuildings2024-12-01 2025-11-30 02575564core:FurnitureFittings2024-12-01 2025-11-30 02575564core:OfficeEquipment2024-12-01 2025-11-30 02575564core:Vehicles2024-12-01 2025-11-30 02575564core:PlantMachinery2024-12-01 2025-11-30 02575564core:OtherPropertyPlantEquipment2024-12-01 2025-11-30 02575564core:LandBuildings2025-11-30 02575564core:PlantMachinery2025-11-30 02575564core:Vehicles2025-11-30 02575564core:FurnitureFittings2025-11-30 02575564core:OfficeEquipment2025-11-30 02575564core:OtherPropertyPlantEquipment2025-11-30 02575564core:Right-of-useAssets2024-12-01 2025-11-30 02575564core:Right-of-useAssets2025-11-30 02575564core:Goodwill2024-12-01 2025-11-30 02575564core:PatentsTrademarksLicencesConcessionsSimilar2024-12-01 2025-11-30 02575564core:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-12-01 2025-11-30 02575564core:OtherResidualIntangibleAssets2024-12-01 2025-11-30 02575564core:Goodwill2025-11-30 02575564core:DevelopmentCostsCapitalisedDevelopmentExpenditure2025-11-30 02575564core:PatentsTrademarksLicencesConcessionsSimilar2025-11-30 02575564core:OtherResidualIntangibleAssets2025-11-30 02575564dpl:CostSales2024-12-01 2025-11-30 02575564dpl:AdministrativeExpenses2024-12-01 2025-11-30 02575564dpl:DistributionCosts2024-12-01 2025-11-30025755642023-12-01 025755642024-11-30 025755642023-12-01 2024-11-30 02575564core:WithinOneYear2024-11-30 02575564core:AfterOneYear2024-11-30 02575564core:CurrentFinancialInstruments2024-11-30 02575564core:Non-currentFinancialInstruments2024-11-30 02575564core:LandBuildings2024-11-30 02575564core:PlantMachinery2024-11-30 02575564core:Vehicles2024-11-30 02575564core:FurnitureFittings2024-11-30 02575564core:OfficeEquipment2024-11-30 02575564core:OtherPropertyPlantEquipment2024-11-30 02575564core:Right-of-useAssets2024-11-30 02575564core:Goodwill2024-11-30 02575564core:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-11-30 02575564core:PatentsTrademarksLicencesConcessionsSimilar2024-11-30 02575564core:OtherResidualIntangibleAssets2024-11-30 02575564dpl:AdministrativeExpenses2023-12-01 2024-11-3002575564bus:Director12024-12-01 2025-11-3002575564bus:Director22024-12-01 2025-11-3002575564bus:Director32024-12-01 2025-11-3002575564bus:PrivateLimitedCompanyLtd2024-12-01 2025-11-30
Selective Antibodies Limited
Unaudited Financial Statements
for the year ended 30 November 2025
Company registration number 02575564
(England and Wales)

Company Information

For the year ended 30 November 2025
Directors Cunningham, Declan Thomas
Self, Colin Henry, Professor
Cole, William Gwyn

Company secretary Self, Ingeborg Renata

Registered office 2 Gosforth Park Avenue
Newcastle Upon Tyne
NE12 8EG

Registered number 02575564

Accountant Declan Cunningham Limited

Statement of Financial Position

As at 30 November 2025
2025
2024
£
£
£
£
Fixed assets
10,078
-
Current assets
55,092
13,758
Creditors amounts falling due within one year
(10,453)
(2,856)
Net current assets (liabilities)
44,639
10,902
Total assets less current liabilities
54,717
10,902
Creditors amounts falling due after one year
(750)
(250)
Net assets (liabilities)
53,967
10,652
Capital and reserves
53,967
10,652

Notes to the Financial Statements

1. Employees

The average number of employees during the year was 0 (2024: 0).
The company is a private company limited by shares and registered in England and Wales. It was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.
These financial statements have been prepared in accordance with the micro-entity provisions and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved and authorised for issue by the Board of Directors on 31 August 2026 and are signed on its behalf by:

Cunningham, Declan Thomas
Cunningham, Declan Thomas
Director

Company registration number 02575564